Trial Profile
A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Enterovirus A vaccine (Primary)
- Indications Enterovirus A infections
- Focus Therapeutic Use
- 01 Jan 2017 Primary endpoint of EV71-associated diseases has been met, according to results published in the Journal of Infectious Diseases.
- 01 Jan 2017 Results published in the Journal of Infectious Diseases
- 03 Jun 2013 Results published in the Lancet [online].